The impending loss of exclusivity (LoE) for Keytruda and the PD-(L)1 class of immunotherapies does not signal the end of this pathway’s utility, but rather marks an interesting time-point in the protein’s seemingly enduring position in oncology.
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only can we observe an emerging role for these products in combination regimens with small molecules and other mAbs, but also as part of new oncology modalities, including bispecific antibodies (bsAbs), mRNA immunotherapies, antibody-drug conjugates (ADCs), and antibody-radioconjugates (ARCs). Such forward-thinking uses will likely continue to entrench PD-(L)1 targeting as a cornerstone of modern oncology.
In this second part of an ongoing series examining PD-(L)1s and advancements in oncology treatment, Aaron Everitt further explores the exciting opportunities that lie ahead.
